Connection

SUSAN HILSENBECK to Molecular Targeted Therapy

This is a "connection" page, showing publications SUSAN HILSENBECK has written about Molecular Targeted Therapy.
Connection Strength

0.417
  1. HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer. Clin Cancer Res. 2017 Sep 01; 23(17):5123-5134.
    View in: PubMed
    Score: 0.116
  2. Retrospective review of genomic testing in breast cancer: Does it improve outcome? Breast Cancer Res Treat. 2017 May; 163(1):191-195.
    View in: PubMed
    Score: 0.114
  3. Modernizing Eligibility Criteria for Molecularly Driven Trials. J Clin Oncol. 2015 Sep 01; 33(25):2815-20.
    View in: PubMed
    Score: 0.102
  4. HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. J Natl Cancer Inst. 2020 01 01; 112(1):46-54.
    View in: PubMed
    Score: 0.035
  5. Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy. Clin Cancer Res. 2015 Sep 01; 21(17):3995-4003.
    View in: PubMed
    Score: 0.025
  6. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. Breast Cancer Res. 2014 Sep 11; 16(5):430.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.